12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Keppra levetiracetam regulatory update

FDA issued a new quarterly report on safety information emerging from its Adverse Events Reporting System (AERS) during 3Q10 in which the agency identified a possible risk of Stevens-Johnson's Syndrome...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >